These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35241123)

  • 21. Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.
    Ferraresi M; Panzieri DL; Leoni S; Cappellini MD; Kattamis A; Motta I
    Eur J Pediatr; 2023 Jun; 182(6):2509-2519. PubMed ID: 36997768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoothing the crescent curve: sickle cell disease.
    Talano JA; Cairo MS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):468-74. PubMed ID: 25696896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
    Ross JM; Forté S; Soulières D
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):211-224. PubMed ID: 35912835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 gene editing for curing sickle cell disease.
    Park SH; Bao G
    Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
    Obadina M; Wilson S; Derebail VK; Little J
    Kidney360; 2023 Jul; 4(7):997-1005. PubMed ID: 37254256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. cGMP modulation therapeutics for sickle cell disease.
    Conran N; Torres L
    Exp Biol Med (Maywood); 2019 Feb; 244(2):132-146. PubMed ID: 30691292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
    Weaver SB; Rungkitwattanakul D; Singh D
    J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies.
    Sánchez LM; Morrone K; Frei-Jones M; Fasipe TA
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e277-e283. PubMed ID: 38718300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. End Organ Affection in Sickle Cell Disease.
    Bathla T; Lotfollahzadeh S; Quisel M; Mehta M; Malikova M; Chitalia VC
    Cells; 2024 May; 13(11):. PubMed ID: 38891066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizanlizumab in sickle cell disease.
    Kaur K; Kennedy K; Liles D
    Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Options for Sickle Cell Disease.
    Meier ER
    Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic Cell Transplantation for Sickle Cell Disease.
    Krishnamurti L
    Front Pediatr; 2020; 8():551170. PubMed ID: 33469520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Therapies for the Management of Sickle Cell Disease.
    Rai P; Ataga KI
    F1000Res; 2020; 9():. PubMed ID: 32765834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape.
    Kassim AA; Sharma D
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):259-266. PubMed ID: 28641096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.